Deans' stroke musings: CorTec’s CEO Says FDA Breakthrough Marks Shift To Therapeutic BCI For Stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, April 10, 2026

CorTec’s CEO Says FDA Breakthrough Marks Shift To Therapeutic BCI For Stroke

Can't see this all of this since I'm not in business anymore. But if this is reading signals from the motor cortex it won't help persons like me whose motor cortex is dead.

CorTec’s CEO Says FDA Breakthrough Marks Shift To Therapeutic BCI For Stroke

CorTec secured US FDA breakthrough device designation for an implantable BCI that restores motor function in stroke patients. With the device implanted in two patients and a third to come, CorTec now eyes larger trials and a $40m-$50m funding raise.

Germany-based CorTec GmbH has received US FDA beakthrough device designation for its brain-computer interface (BCI) system designed to restore motor function in stroke patients.

Germany-based CorTec GmbH has received US Food and Drug Administration breakthrough device designation for its brain-computer interface (BCI) system designed to restore motor function in stroke patients.